JP2002514594A5 - - Google Patents

Download PDF

Info

Publication number
JP2002514594A5
JP2002514594A5 JP2000547972A JP2000547972A JP2002514594A5 JP 2002514594 A5 JP2002514594 A5 JP 2002514594A5 JP 2000547972 A JP2000547972 A JP 2000547972A JP 2000547972 A JP2000547972 A JP 2000547972A JP 2002514594 A5 JP2002514594 A5 JP 2002514594A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
alkyl
animal
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000547972A
Other languages
English (en)
Other versions
JP5057003B2 (ja
JP2002514594A (ja
Filing date
Publication date
Priority claimed from PCT/NO1998/000143 external-priority patent/WO1999058120A1/en
Application filed filed Critical
Publication of JP2002514594A publication Critical patent/JP2002514594A/ja
Publication of JP2002514594A5 publication Critical patent/JP2002514594A5/ja
Application granted granted Critical
Publication of JP5057003B2 publication Critical patent/JP5057003B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】
一般式(I):
CH−[CHx−CH −COOR
(式中、mは0乃至23の整数であり
xはS及びSeを含む群から選択され、
Rは水素又はC−Cアルキルであ)で示される脂肪酸類似体又はその塩の、肥満の予防用の医薬組成物を調製するための使用。
【請求項2】
m≧13である、請求項1に記載の使用。
【請求項3】
xがイオウである、請求項1に記載の使用。
【請求項4】
xがセレンである、請求項1に記載の使用。
【請求項5】
動物における肥満又は過体重状態の予防のための、請求項1に記載の使用。
【請求項6】
前記動物がヒトである、請求項5に記載の使用。
【請求項7】
前記動物が、キジ類のトリ、ウシ、ヒツジ、ヤギ又はブタ哺乳動物を含む農業用動物である、請求項5に記載の使用。
【請求項8】
前記動物が、イヌ又はネコを含む家畜又は愛玩動物である、請求項5に記載の使用。
【請求項9】
前記動物が、サケ、タラ、テラピア、ハマグリ、カキ、ロブスター又はカニを含む魚貝類である、請求項5に記載の使用。
【請求項10】
前記医薬組成物が、前記脂肪酸類似体又はその塩の予防的に有効な濃度がその投与の期間に動物の血中に実質的に持続的に維持されるように投与されるものとして意図されていることを特徴とする、請求項1に記載の使用。
【請求項11】
前記医薬組成物が単位剤形であることを特徴とする、請求項1に記載の使用。
【請求項12】
一般式(I):
CH−[CHx−CH −COOR
(式中、mは0乃至23の整数であり
xはS及びSeを含む群から選択され、
Rは水素又はC−Cアルキルであ)で示される新規な脂肪酸類似体又はその塩。
【請求項13】
動物における肥満の予防のための医薬組成物であって、前記医薬組成物が、一般式(I):
CH−[CHx−CH −COOR
(式中、mは0乃至23の整数であり
xはS及びSeを含む群から選択され、
Rは水素又はC−Cアルキルであ)で示される脂肪酸類似体又はその塩を含む医薬組成物。
【請求項14】
前記医薬組成物が脂肪酸類似体と混和物の形で製剤学的に許容される担体又は賦形剤を含む、請求項13に記載の医薬組成物。
【請求項15】
m≧13である、請求項13に記載の医薬組成物。
【請求項16】
xがイオウである、請求項13に記載の医薬組成物。
【請求項17】
xがセレンである、請求項13に記載の医薬組成物。
Figure 2002514594
BH
4.アルキル−Se−Se−アルキル ⇒ 2アルキル−Se
5.アルキル−Se + Hal−CH −COOH ⇒ アルキル−Se−CH−COOH
例えば、アルキルがテトラデシルであるときの最終化合物、(CH−(CH13Se−CH−COOH(テトラデシルセレノ酢酸(TSA))は、ジエチルエーテル及びヘキサンからの結晶化により精製することができる。この産物は、NMR、IR及び分子量測定法により完全に特徴づけられうる。
JP2000547972A 1998-05-08 1999-04-23 肥満、高血圧及び脂肪肝の治療用の新規な脂肪類似体 Expired - Fee Related JP5057003B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NONO9800143 1998-05-08
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
NO9800143 1998-05-08
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (3)

Publication Number Publication Date
JP2002514594A JP2002514594A (ja) 2002-05-21
JP2002514594A5 true JP2002514594A5 (ja) 2012-03-01
JP5057003B2 JP5057003B2 (ja) 2012-10-24

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000547972A Expired - Fee Related JP5057003B2 (ja) 1998-05-08 1999-04-23 肥満、高血圧及び脂肪肝の治療用の新規な脂肪類似体
JP2000547973A Pending JP2002514595A (ja) 1998-05-08 1999-04-23 糖尿病の治療用の新規な脂肪類似体
JP2000547974A Expired - Fee Related JP4465672B2 (ja) 1998-05-08 1999-05-07 再狭窄の治療及び/又は予防用の医薬組成物並びにそれを調製するためのttaの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2000547973A Pending JP2002514595A (ja) 1998-05-08 1999-04-23 糖尿病の治療用の新規な脂肪類似体
JP2000547974A Expired - Fee Related JP4465672B2 (ja) 1998-05-08 1999-05-07 再狭窄の治療及び/又は予防用の医薬組成物並びにそれを調製するためのttaの使用

Country Status (18)

Country Link
US (4) US6365628B1 (ja)
EP (5) EP1075259B1 (ja)
JP (3) JP5057003B2 (ja)
KR (3) KR100701503B1 (ja)
CN (3) CN1223343C (ja)
AT (5) ATE336239T1 (ja)
AU (4) AU7240398A (ja)
BR (2) BR9910296A (ja)
CA (3) CA2331395C (ja)
DE (5) DE69932864D1 (ja)
DK (3) DK1075259T3 (ja)
ES (3) ES2204142T3 (ja)
HK (3) HK1034909A1 (ja)
NO (3) NO20005463L (ja)
NZ (3) NZ508047A (ja)
PT (2) PT1075259E (ja)
RU (3) RU2219920C2 (ja)
WO (4) WO1999058120A1 (ja)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
JP5008258B2 (ja) 2002-06-20 2012-08-22 アイシー・ベック・リミテッド 含硫黄ホスホリピド誘導体
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
US7705016B2 (en) 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
CN1934072A (zh) * 2004-01-30 2007-03-21 派普林生物脂股份有限公司 治疗和载体分子
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
CN1961213A (zh) * 2004-05-28 2007-05-09 詹森药业有限公司 新的在清醒大鼠中静脉给药和血液取样模型
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NZ553261A (en) * 2004-07-19 2010-12-24 Thia Medica As Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
BRPI0611159A2 (pt) * 2005-05-04 2012-07-31 Pronova Biopharma Norge As composto e respectivo processo e fabrico, composiÇÕes farmacÊutica e de Ácido graxo, usos de composto e mÉtodos de controle da reduÇço do peso corpàreo e/ou prevenÇço do ganho de peso corpàreo, de tratamento e/ou prevenÇço da obesidade ou de uma condiÇço de sobrepeso, do diabete, de doenÇas relacionadas com a amiloidose, de tratamento ou profilaxia de fatores méltiplos de risco para doenÇas cardiovasculares e de prevenÇço do derrame cerebral, de ataques isquÊmicos cerebrais ou passageiros relacionados com a aterosclerose de vÁrias artÉrias
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
EP2083817A4 (en) * 2006-10-20 2009-12-23 Cpd Llc METHOD FOR RECONSTRUCTING THE EFFECT OF INCRETIN
KR101544584B1 (ko) * 2006-11-01 2015-08-13 프로노바 바이오파마 너지 에이에스 오메가-3 지질 화합물
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2722114A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
MX366137B (es) 2009-05-08 2019-06-28 Pronova Biopharma Norge As Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios.
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
JP2014505017A (ja) 2010-11-05 2014-02-27 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物を用いる処置方法
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
CA2904827C (en) 2013-03-11 2020-10-27 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び/又は治療のための使用
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
US10792266B2 (en) 2017-10-23 2020-10-06 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
EP3934639A4 (en) * 2019-03-04 2023-01-11 Epitracker, Inc. FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Similar Documents

Publication Publication Date Title
JP2002514594A5 (ja)
RU2000131222A (ru) Новые аналоги жирных кислот для лечения ожирения, гипертензии и жировой инфильтрации печени
AU2689699A (en) Small molecules that increase the conversion of food to body weight gain
CA2058754C (en) Divalent metal salts of indomethacin
JPS6312043B2 (ja)
JP2007515402A5 (ja)
CA2235902C (en) Method for treating protozoal infections
JPH0359882B2 (ja)
WO2007142707A1 (en) Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
RU2005104894A (ru) Способ повышения мясной продуктивности молодняка свиней на откорме
US7045150B2 (en) Tellurium containing nutrient formulation and process for enhancing the cumulative weight gain or feed efficacy in poultry
JP3534792B2 (ja) 抗病性飼料
US20190191740A1 (en) Methods to Promote Growth and Improve Feed Conversion in Animals
EP0407405A1 (en) Method for treating hoof thrush and hoof rot
CA1072013A (en) Method of enhancing reproductive efficiency in non-human animals
JP2011182748A (ja) 家畜又は家禽用飼料
JPS6324858A (ja) 動物飼料
JP4629964B2 (ja) ウシの消化器疾患治療剤
WO2002003813A1 (en) Use of dammarane-type triterpenoid saponins
Murray Effect of insulin, adrenal cortical hormones, salt and dl-alanine on carbohydrate metabolism in scurvy.
JPWO2007037098A1 (ja) 繁殖障害改善剤
JP2005501008A5 (ja)
RU2005140156A (ru) Применение аивлозина для лечения болезней, вызванных brachyspira pilosicoli или ornithobacterium rhinotracheale
JP3981770B2 (ja) 抗ロタウイルス剤、及びその用途
JP3014784B2 (ja) 魚類のストレス防止用薬剤